Astellas Pharma Inc.
ALPMYOTCHealthcare● Active
$13.49
+$0.26(+1.97%)
Market Cap$24.2B
P/E Ratio—
52W High$17.35
52W Low$9.11
Astellas Pharma Inc. (ALPMY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALPMY · earnings · updated Jun 10, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 27, 2026EPS Actual
$0.33
Est. $0.19 · +70.0%
Revenue
$3.37B
Est. $3.28B · +2.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 27, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 10-Quarter EPS Beat Streak
ALPMY reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $0.31 | — | — | — | $3.52B | — |
| ▲ Q2 FY2026 | Apr 27, 2026 | $0.19 | $0.33 | +70.0% | $3.37B | $3.28B | +2.8% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $0.29 | $0.36 | +24.8% | $3.64B | $3.38B | +7.6% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.20 | $0.30 | +50.5% | $3.56B | $3.42B | +3.9% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.14 | $0.40 | +195.0% | $3.49B | $3.24B | +8.0% |
| ▲ Q2 FY2025 | Apr 25, 2025 | $0.15 | $0.27 | +84.3% | $3.16B | $3.16B | -0.1% |
| ▲ Q1 FY2025 | Feb 4, 2025 | $0.16 | $0.30 | +89.9% | $3.29B | $2.91B | +13.1% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $0.12 | $0.13 | +7.5% | $3.11B | $2.96B | +5.1% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026Beat
EPS Actual
$0.33
EPS Est.
$0.19
EPS Surpr.
+70.0%
Revenue
$3.37B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$0.36
EPS Est.
$0.29
EPS Surpr.
+24.8%
Revenue
$3.64B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.20
EPS Surpr.
+50.5%
Revenue
$3.56B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.40
EPS Est.
$0.14
EPS Surpr.
+195.0%
Revenue
$3.49B
Q2 FY2025
Apr 25, 2025Beat
EPS Actual
$0.27
EPS Est.
$0.15
EPS Surpr.
+84.3%
Revenue
$3.16B
Q1 FY2025
Feb 4, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.16
EPS Surpr.
+89.9%
Revenue
$3.29B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$0.13
EPS Est.
$0.12
EPS Surpr.
+7.5%
Revenue
$3.11B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $22.20 | $22.74 | $23.44 | 1 |
| Q4 FY2026 | $56.42 | $57.79 | $59.57 | 1 |
| Q3 FY2026 | $51.65 | $52.90 | $54.54 | 1 |
| Q2 FY2026 | $49.08 | $50.28 | $51.83 | 1 |
| Q1 FY2026 | $30.27 | $31.01 | $31.97 | 1 |
| Q4 FY2025 | $44.66 | $45.75 | $47.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $534B | $544B | $556B | 1 |
| Q4 FY2026 | $602B | $613B | $628B | 1 |
| Q3 FY2026 | $569B | $579B | $593B | 2 |
| Q2 FY2026 | $553B | $563B | $576B | 2 |
| Q1 FY2026 | $514B | $523B | $536B | 3 |
| Q4 FY2025 | $484B | $531B | $560B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 27, 2026 | +70.0% | $15.43 | $15.05 | -2.46% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +24.8% | $14.11 | $15.35 | +8.79% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +50.5% | $10.28 | $10.90 | +6.03% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +195.0% | $10.07 | $10.35 | +2.78% |
| ▲ Q2 FY2025 | Apr 25, 2025 | +84.3% | $9.57 | $10.07 | +5.22% |
| ▲ Q1 FY2025 | Feb 4, 2025 | +89.9% | $9.52 | $9.15 | -3.89% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +7.5% | $11.64 | $12.30 | +5.67% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +300.0% | $11.61 | $12.30 | +5.94% |
Q2 FY2026-2.46%
Report Date
Apr 27, 2026
EPS Beat/Miss
+70.0%
Price Before
$15.43
Price After
$15.05
Q1 FY2026+8.79%
Report Date
Feb 4, 2026
EPS Beat/Miss
+24.8%
Price Before
$14.11
Price After
$15.35
Q4 FY2025+6.03%
Report Date
Oct 30, 2025
EPS Beat/Miss
+50.5%
Price Before
$10.28
Price After
$10.90
Q3 FY2025+2.78%
Report Date
Jul 30, 2025
EPS Beat/Miss
+195.0%
Price Before
$10.07
Price After
$10.35
Q2 FY2025+5.22%
Report Date
Apr 25, 2025
EPS Beat/Miss
+84.3%
Price Before
$9.57
Price After
$10.07
Q1 FY2025-3.89%
Report Date
Feb 4, 2025
EPS Beat/Miss
+89.9%
Price Before
$9.52
Price After
$9.15
Q4 FY2024+5.67%
Report Date
Oct 30, 2024
EPS Beat/Miss
+7.5%
Price Before
$11.64
Price After
$12.30
Q3 FY2024+5.94%
Report Date
Aug 1, 2024
EPS Beat/Miss
+300.0%
Price Before
$11.61
Price After
$12.30
Avg Beat Reaction+3.51%
Beat Rate8 / 8 quarters
Largest Move+8.79% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALPMY ends December
Astellas Pharma Inc. (ALPMY) most recently reported earnings on April 27, 2026 for Q2 FY2026, posting EPS of $0.33 — beating the analyst consensus of $0.19 by +70.0%. ALPMY has beaten EPS estimates for 10 consecutive quarters.
Each quarter, investors track ALPMY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALPMY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALPMY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALPMY earnings · 5 questionsAstellas Pharma Inc.'s next earnings report is expected around TBD. ALPMY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALPMY historically reports after market close (AMC).
ALPMY earnings datewhen is ALPMY earningsALPMY next earnings datewhen does ALPMY report earningsALPMY earnings calendar
▸ Source: FMP · Astellas Pharma Inc. SEC filings · US GAAP · Astellas Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026